Alvogyl Versus Platelet-Rich Fibrin for Healing of Alveolar Osteitis

Alveolar osteitis, commonly known as dry socket, is a painful complication that can occur after tooth extraction, particularly following removal of a mandibular third molar. It occurs when normal healing of the extraction socket is disrupted and is commonly associated with significant pain and delayed healing. Alvogyl is a commonly used dressing for managing dry socket and can provide rapid pain relief. Platelet-rich fibrin (PRF) is a preparation made from the patient's own blood that contains platelets, white blood cells, fibrin, and growth factors that may promote tissue repair and wound healing. This randomized controlled clinical trial will compare Alvogyl and platelet-rich fibrin in patients diagnosed with alveolar osteitis following third molar extraction. A total of 102 eligible adult participants will be randomly assigned to receive either Alvogyl or PRF as treatment for the affected extraction socket. The study will compare the healing outcomes of the two treatments by assessing pain intensity and the number of exposed socket walls during follow-up. Pain will be assessed using a visual analogue scale, while socket healing will be evaluated clinically by recording the number of exposed socket walls. The study aims to determine whether PRF provides better healing outcomes than conventional Alvogyl treatment for alveolar osteitis. The findings may help clinicians select an effective treatment approach for reducing pain and promoting healing in patients with dry socket.

Inclusion Criteria: 1. Adults aged 18 years or older. 2. Participants of either sex. 3. Patients presenting with alveolar osteitis following third molar extraction, diagnosed according to the study's operational definition. 4. Patients willing to participate in the study and provide informed consent. 5. Patients willing and able to attend the scheduled postoperative follow-up assessments. Exclusion Criteria: 1. Patients with a smoking habit. 2. Patients with a history of bleeding disorders. 3. Patients unwilling or unable to attend the required follow-up sessions. 4. Patients with a history of hypertension, diabetes mellitus, liver disease, or renal disease. 5. Pregnant or breastfeeding individuals. 6. Patients using medications that may affect healing or study outcomes, including bisphosphonates, systemic steroids, or antidepressants.